HDAC9 and diffuse midline glioma: In 2023, Monje et al. [202]evaluated the safety and tolerability of Panobinostat, a multi-histone deacetylase (HDAC) oral inhibitor, in pediatric patients with progressive DIPG and diffuse midline glioma.